Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Oct 1;45(10):1842-1853.
doi: 10.1097/IAE.0000000000004534.

VISUAL OUTCOMES AND CLINICAL FEATURES OF EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN

Letícia de Oliveira Audi  1 , Ricardo A P de Carvalho  2 , Antônio M Casella  3 , Lourdes Aiko H Maniero  4 , Claudio Zett  5 , André M V Messias  1 , Fabrício T Borges  6 , Francyne Veiga R Cyrino  1 , Theodomiro Garrido  7 , Thais M A Bastos  1 , Maria Inêz C Costa  8 , Juliana L Orefice  9 , João Vítor T Marques  10 , Raul N G Vianna  11 , Arnaldo P Cialdini  12 , Érika P M Diniz  13 , Carlos A Moreira-Neto  9 , Carlos A Moreira Jr  9 , Marcos P Ávila  12 , Sérgio Pimentel  14 , Michel E Farah  3 , Rodrigo Jorge  1 , Luiz H Lima  3
Affiliations
Observational Study

VISUAL OUTCOMES AND CLINICAL FEATURES OF EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN

Letícia de Oliveira Audi et al. Retina. .

Abstract

Purpose: To describe extensive macular atrophy with pseudodrusen using multimodal imaging and analyze factors associated with visual loss.

Methods: This observational case series retrospectively reviewed the clinical and multimodal imaging (color fundus photography, fluorescein angiography, fundus autofluorescence, and optical coherence tomography) of patients between January and December 2023. The extensive macular atrophy with pseudodrusen diagnosis was based on early-onset macular atrophy, pseudodrusen, and bilateral disease. Univariate and multivariate Tobit regression models identified and ranked imaging findings and risk factors ( P < 0.05) for visual loss.

Results: Seventy-four patients (52.7% women) were diagnosed with extensive macular atrophy with pseudodrusen; 86.5% had a history of rheumatic fever, and nearly 17% had heart valve disease. Mean age at onset was 58.7 years (range, 43-73 years), and the mean best-corrected visual acuity was 20/60 (range, 20/800-20/20). Color fundus photography or fundus autofluorescence identified pseudodrusen in 91.7% and 93.0% of eyes, respectively, and optical coherence tomography did so in all evaluable patients. Fundus autofluorescence revealed a hyperautofluorescent edge around the hypoautofluorescent central lesion in 86.6% of eyes. Optical coherence tomography showed a diffuse pseudodrusen pattern in 88.9%, outer retinal loss/thinning in 80.8%, and macular neovascularization in 9.4% of eyes. Subfoveal choroidal thickness ( P = 0.004), outer retinal loss/thinning ( P < 0.01), and preserved fovea ( P < 0.01) were associated significantly with visual acuity. Visual loss was associated with younger age at diagnosis ( P = 0.04) and coexistence of rheumatic fever and heart valve disease ( P = 0.006).

Conclusion: Early diagnosis and treatment of rheumatic fever complications may be related to extensive macular atrophy with pseudodrusen progression and outcomes. Longitudinal studies should characterize the natural history of extensive macular atrophy with pseudodrusen.

Keywords: extensive macular atrophy with pseudodrusen; heart valve disease; multimodal imaging analysis; rheumatic fever; risk factors; visual outcomes.

PubMed Disclaimer

References

    1. Hamel CP, Meunier I, Arndt C, et al. Extensive macular atrophy with pseudodrusen-like appearance: a new clinical entity. Am J Ophthalmol 2009;147:609–620.
    1. Douillard A, Picot MC, Delcourt C, et al. Clinical characteristics and risk factors of extensive macular atrophy with pseudodrusen: the EMAP case-control national clinical trial. Ophthalmology 2016;123:1865–1873.
    1. Boon CJ, Theelen T, Hoyng CB. Extensive macular atrophy with pseudodrusen-like appearance: a new clinical entity. Am J Ophthalmol 2009;148:173–175.
    1. Douillard A, Picot MC, Delcourt C, et al. Dietary, environmental, and genetic risk factors of extensive macular atrophy with pseudodrusen, a severe bilateral macular atrophy of middle-aged patients. Sci Rep 2018;8:6840.
    1. Rajabian F, Arrigo A, Bordato A, et al. Optical coherence tomography angiography in extensive macular atrophy with pseudodrusen-like appearance. Transl Vis Sci Technol 2020;9:2.

Publication types

LinkOut - more resources